Single dose study of new antimalarial drug to evaluate blood levels in healthy volunteers

Phase 1 Single dose pharmacokinetic study of CDRI compound 97/78, a novel antimalarial drug in healthy human volunteers - No acronym

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/07/002832

Enrollment

Registered

2012-07-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: CDRI9778: dose: 200 mg frequency - single dose duration - one dose route of administration - oral Control Intervention1: None: It is a single arm study Control Intervention2: none: dose

Eligibility

Inclusion criteria

Inclusion criteria: Healthy adult males Blood biochemistry and hematology - wnl Stool and urine R/E - normal

Exclusion criteria

Exclusion criteria: Any medical or psychiatric illness History of drug abuse Refusal to give consent

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic analysisTimepoint: Last sample at 144 hours	—

Secondary

Measure	Time frame
NoneTimepoint: N/A	—

Countries

India

Contacts

Public ContactDr Nusrat Shafiq

PGIMER

nusrat_shafiq@hotmail.com0172-2755254

Outcome results